Sino Biological has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus.
The new Omicron product line includes recombinant Omicron spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognising the Omicron spike protein, and the Omicron pseudovirus assay CRO service. These reagents will help scientists and researchers to understand the impact of the new Omicron mutations on viral transmission as well as therapeutic neutralising antibody and prophylactic vaccine effectiveness.
“Sino Biological produced the key spike protein reagents within a record 11 days in January 2020 and supported thousands of scientists and researchers in over 70 countries worldwide for their Covid-19 research which led to close to 1000 publications to date” Sino Biological CEO Dr. Jie Zhang said. “We are very pleased to be able to produce the Omicron RBD protein in a new record of six days, spike binding antibody in eight days, and the spike-S1, S-ECD trimer proteins and pseudovirus in ten days. We’ll continue to monitor new mutations, and make sure we make research tools available to scientists as quickly as we possibly can.”
